vs

Side-by-side financial comparison of AtriCure, Inc. (ATRC) and Black Stone Minerals, L.P. (BSM). Click either name above to swap in a different company.

AtriCure, Inc. is the larger business by last-quarter revenue ($140.5M vs $95.2M, roughly 1.5× Black Stone Minerals, L.P.). On growth, AtriCure, Inc. posted the faster year-over-year revenue change (13.1% vs -8.7%). Over the past eight quarters, AtriCure, Inc.'s revenue compounded faster (13.6% CAGR vs -9.7%).

AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.

Black Stone Minerals, L.P., or Black Stone Minerals, is a Houston, Texas-based oil and natural gas corporation.

ATRC vs BSM — Head-to-Head

Bigger by revenue
ATRC
ATRC
1.5× larger
ATRC
$140.5M
$95.2M
BSM
Growing faster (revenue YoY)
ATRC
ATRC
+21.8% gap
ATRC
13.1%
-8.7%
BSM
Faster 2-yr revenue CAGR
ATRC
ATRC
Annualised
ATRC
13.6%
-9.7%
BSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATRC
ATRC
BSM
BSM
Revenue
$140.5M
$95.2M
Net Profit
$72.2M
Gross Margin
75.0%
Operating Margin
1.8%
78.6%
Net Margin
75.9%
Revenue YoY
13.1%
-8.7%
Net Profit YoY
55.8%
EPS (diluted)
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRC
ATRC
BSM
BSM
Q4 25
$140.5M
$95.2M
Q3 25
$134.3M
$105.2M
Q2 25
$136.1M
$106.7M
Q1 25
$123.6M
$115.3M
Q4 24
$124.3M
$104.3M
Q3 24
$115.9M
$103.2M
Q2 24
$116.3M
$115.2M
Q1 24
$108.9M
$116.8M
Net Profit
ATRC
ATRC
BSM
BSM
Q4 25
$72.2M
Q3 25
$-267.0K
$91.7M
Q2 25
$-6.2M
$120.0M
Q1 25
$-6.7M
$15.9M
Q4 24
$46.3M
Q3 24
$-7.9M
$92.7M
Q2 24
$-8.0M
$68.3M
Q1 24
$-13.3M
$63.9M
Gross Margin
ATRC
ATRC
BSM
BSM
Q4 25
75.0%
Q3 25
75.5%
Q2 25
74.5%
Q1 25
74.9%
Q4 24
74.5%
Q3 24
74.9%
Q2 24
74.7%
Q1 24
74.7%
Operating Margin
ATRC
ATRC
BSM
BSM
Q4 25
1.8%
78.6%
Q3 25
0.2%
89.5%
Q2 25
-4.5%
Q1 25
-4.8%
14.9%
Q4 24
-11.7%
45.6%
Q3 24
-6.4%
90.2%
Q2 24
-6.2%
59.5%
Q1 24
-10.0%
54.8%
Net Margin
ATRC
ATRC
BSM
BSM
Q4 25
75.9%
Q3 25
-0.2%
87.2%
Q2 25
-4.5%
112.5%
Q1 25
-5.5%
13.8%
Q4 24
44.4%
Q3 24
-6.8%
89.9%
Q2 24
-6.9%
59.3%
Q1 24
-12.2%
54.7%
EPS (diluted)
ATRC
ATRC
BSM
BSM
Q4 25
$0.04
Q3 25
$-0.01
Q2 25
$-0.13
Q1 25
$-0.14
Q4 24
$-0.33
Q3 24
$-0.17
Q2 24
$-0.17
Q1 24
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRC
ATRC
BSM
BSM
Cash + ST InvestmentsLiquidity on hand
$167.4M
$1.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$491.9M
Total Assets
$654.2M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRC
ATRC
BSM
BSM
Q4 25
$167.4M
$1.5M
Q3 25
$147.9M
$2.9M
Q2 25
$117.8M
$2.5M
Q1 25
$99.9M
$2.4M
Q4 24
$122.7M
$2.5M
Q3 24
$130.3M
$21.0M
Q2 24
$114.0M
$26.7M
Q1 24
$106.0M
$40.5M
Total Debt
ATRC
ATRC
BSM
BSM
Q4 25
Q3 25
$61.9M
Q2 25
$61.9M
Q1 25
$61.9M
Q4 24
Q3 24
$61.9M
Q2 24
$61.9M
Q1 24
$61.9M
Stockholders' Equity
ATRC
ATRC
BSM
BSM
Q4 25
$491.9M
Q3 25
$476.5M
Q2 25
$464.5M
Q1 25
$454.6M
Q4 24
$461.0M
Q3 24
$465.0M
Q2 24
$462.1M
Q1 24
$456.3M
Total Assets
ATRC
ATRC
BSM
BSM
Q4 25
$654.2M
$1.3B
Q3 25
$635.4M
$1.3B
Q2 25
$608.8M
$1.3B
Q1 25
$591.6M
$1.2B
Q4 24
$609.3M
$1.2B
Q3 24
$615.1M
$1.2B
Q2 24
$597.3M
$1.2B
Q1 24
$591.6M
$1.2B
Debt / Equity
ATRC
ATRC
BSM
BSM
Q4 25
Q3 25
0.13×
Q2 25
0.13×
Q1 25
0.14×
Q4 24
Q3 24
0.13×
Q2 24
0.13×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRC
ATRC
BSM
BSM
Operating Cash FlowLast quarter
$20.0M
$65.1M
Free Cash FlowOCF − Capex
$18.4M
FCF MarginFCF / Revenue
13.1%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$48.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRC
ATRC
BSM
BSM
Q4 25
$20.0M
$65.1M
Q3 25
$26.7M
$99.8M
Q2 25
$21.6M
$80.5M
Q1 25
$-11.0M
$64.8M
Q4 24
$5.8M
$91.0M
Q3 24
$20.0M
$93.2M
Q2 24
$7.4M
$100.4M
Q1 24
$-21.0M
$104.5M
Free Cash Flow
ATRC
ATRC
BSM
BSM
Q4 25
$18.4M
Q3 25
$24.1M
Q2 25
$19.0M
Q1 25
$-13.2M
Q4 24
$3.1M
Q3 24
$16.4M
Q2 24
$5.0M
Q1 24
$-23.8M
FCF Margin
ATRC
ATRC
BSM
BSM
Q4 25
13.1%
Q3 25
18.0%
Q2 25
13.9%
Q1 25
-10.7%
Q4 24
2.5%
Q3 24
14.1%
Q2 24
4.3%
Q1 24
-21.9%
Capex Intensity
ATRC
ATRC
BSM
BSM
Q4 25
1.1%
Q3 25
1.9%
Q2 25
2.0%
Q1 25
1.8%
Q4 24
2.2%
Q3 24
3.1%
Q2 24
2.1%
Q1 24
2.5%
Cash Conversion
ATRC
ATRC
BSM
BSM
Q4 25
0.90×
Q3 25
1.09×
Q2 25
0.67×
Q1 25
4.07×
Q4 24
1.96×
Q3 24
1.01×
Q2 24
1.47×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATRC
ATRC

Appendage Management$45.5M32%
Openheart$38.5M27%
Other$26.2M19%
Pain Management$22.6M16%
Minimally Invasive$7.7M6%

BSM
BSM

Oil Reserves$46.4M49%
Natural Gas Reserves$44.1M46%
Real Estate$4.7M5%

Related Comparisons